Medicofarma Biotech (WAR:MDB) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


WAR:MDB Medicofarma Biotech SA WAR:MDB
28 GF Score
Price zł0.45
GF Value zł0.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medicofarma Biotech Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Medicofarma Biotech's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

WAR:MDB vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicofarma Biotech Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Medicofarma Biotech's Margin of Safety % (DCF Earnings Based) falls into.


WAR:MDB
28GF Score
Medicofarma Biotech SA WAR:MDB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.45 is trading 792% above its estimated GF Value™ of zł0.05. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: zł0.05 vs. price of zł0.45 (792% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
28GF Score

Get the complete analysis for WAR:MDB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.45
Price
zł0.05
GF Value